RT Journal Article SR Electronic T1 Recovery from Immunosuppression-related Disorders in Humans and Animals by IP-PA1, An Edible Lipopolysaccharide JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3113 OP 3118 VO 30 IS 8 A1 TAKEHISA HEBISHIMA A1 YASUNOBU MATSUMOTO A1 GEN WATANABE A1 GEN-ICHIRO SOMA A1 CHIE KOHCHI A1 KAZUYOSHI TAYA A1 YOSHIHIRO HAYASHI A1 YOSHIKAZU HIROTA YR 2010 UL http://ar.iiarjournals.org/content/30/8/3113.abstract AB Immunopotentiator from Pantoea agglomerans 1 (IP-PA1), an edible lipopolysaccharide (LPS) derived from symbiotic bacteria in crops, is a promising immunomodulator. It activates macrophages and protects from chemotherapeutic agent-induced growth inhibition in macrophages in vitro. We showed the immune-recovery effects of IP-PA1 in a chicken model of dexamethasone-induced stress in which IP-PA1 inhibited thymic and bursal atrophy and improved antibody production in response to vaccination. Furthermore, we showed IP-PA1 improved survival of melanoma-bearing, doxorubicin-treated mice, although not directly affecting the proliferation of melanoma cells, dominantly through the improvement of host antitumor immunity. These results suggest that IP-PA1 could have other possible applications in the treatment of various immunosuppression-related disorders in humans and animals.